Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments

Uzan, Catherine; Nikpayam, M.; Ribassin-Majed, Laureen; Gouy, Sébastien; Bendifallah, Sofiane; Cortez, Annie; Rey, Annie; Duvillard, P.; Daraı̈, Émile; Morice, Philippe

doi:10.1093/annonc/mdu139

Cited by 61 publications

(81 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Invasive recurrent disease is the only prognostic factor that can influence patient survival. 6,11 A higher risk for recurrence after FPS compared to RS was confirmed but no effect on OS was observed. 6 Trillsch et al found a higher rate of recurrence in younger patients usually in ovarian tissue, without increased risk for malignant transformation.…”

Section: Discussionmentioning

confidence: 85%

“…6,9,10 The question that arises now is whether this translates into an impaired patient survival. Uzan et al 6 investigated prognostic factors for invasive recurrence and the impact on OS after FPS. Invasive recurrent disease is the only prognostic factor that can influence patient survival.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, fertilitypreserving approach can be justified in young patients with serous borderline tumors. 6,15,16 Sixty-one percent of the patients 40 years or younger had FPS with preservation of parts of a BOT-affected ovary in 25% of these cases. Patients with BOT with childbearing potential and FPS mainly relapse in the remaining ovarian tissue without invasive malignant transformation.…”

Section: Discussionmentioning

confidence: 99%

“…2 Fertility-preserving surgery and younger age are risk factors for recurrence. 5,6 However, little is known about the risk of invasive recurrence, and hence, the impact of FPS on OS. 6 The aim of this study was to determine the OS and progression-free survival (PFS) and the influence of FPS in a large group of patients with serous BOT, diagnosed by one pathologist and treated by the same team during the accrual period.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors

Vancraeynest

Moerman²,

Leunen³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

Objectives: This study aimed to determine the overall survival (OS) and progression-free interval and the influence of fertility-preserving surgery (FPS) versus radical surgery (RS) in patients with serous borderline ovarian tumor (BOT). Methods: Clinical parameters of patients with serous BOT treated between 1993 and 2013 in one institution were retrospectively investigated. All tumors were examined by one pathologist with experience in gynecological pathology. Results: One hundred thirty-two patients with serous BOT (inclusive 16 microinvasive) were analyzed (45% were e40 years), with a median follow-up of 6 years. Thirty-two percent (42/132) of the patients received FPS; 14% (18/132) relapsed (invasive or borderline). The 5-year progression-free survival was 89%. The risk of recurrence was higher in patients 40 years or younger (P = 0.019), after FPS (P = 0.002), in patients with a higher International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.016), for bilateral BOT (P = 0.0132), and for the micropapillary variant (P = 0.067). The OS at 5 years was 97%. There was no statistically significant difference in OS between FPS and RS [all (6 of 90) patients, except for 1, with RS died]. One patient died of relapsed BOT. Among the recurrences, low-grade invasive carcinoma was diagnosed in 4 patients. Three of these 4 patients were originally operated radically, 2 had a micropapillary variant FIGO stage III, and 1 had a papillary pattern FIGO stage II with microinvasion; all 3 had noninvasive implants and are alive. One patient with a micropapillary variant, FIGO stage IIIC with microinvasion and invasive implants, received FPS and died of disease. Conclusions: The risk of recurrence is higher after FPS compared with RS; however, no influence on OS was observed. This was because most of the patients relapsed as BOT. Fertility preservation is justified in young patients with serous borderline tumors.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors

Vancraeynest

Moerman²,

Leunen³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…MPSC represents approximately 6.5%-33% of all SBTs. 10,16,[48][49][50][51] However, there is a consensus that both typical SBTs and MPSC should be classified as LGSC when areas of stromal invasion are greater than 5 mm. Patients with SBT with or without MPSC features have no difference in recurrence or disease-related mortality, although noninvasive SBTs with a micropapillary pattern may have invasive peritoneal implants more often than those without the micropapillary pattern.…”

Section: Role Of Braf Mutation In the Pathogenesis Of Ovarian Cancermentioning

confidence: 99%

BRAF mutational analysis in ovarian tumors: recent perspectives

Wong¹,

Tsai²,

Gershenson³

2015

PLMI

View full text Add to dashboard Cite

BRAF mutations are rare in ovarian cancer and mainly occur in indolent serous borderline tumors (SBTs), also known as serous tumors of low malignant potential or atypical proliferative serous tumors. The reported percentage of BRAF mutations in SBTs varies from 23% to 71%. Although a high percentage of stage II-IV SBTs with noninvasive implants have progressed to invasive low-grade serous carcinomas when patients were observed for 5 years or longer, BRAF mutations are rare in low-grade serous carcinomas as well as in invasive implants associated with SBTs. BRAF mutations in SBTs may prevent SBTs from progressing to invasive carcinomas. On the other hand, the reported percentage of BRAF mutations in mucinous carcinoma (20%) is much higher than that of mucinous borderline tumor (5%). Further investigation of the role of BRAF mutations in SBTs and mucinous tumor will shed light on the molecular mechanism underlying the role of BRAF mutations in tumor progression in different cellular context and the clinical utility of BRAF mutations in SBTs as a biomarker of favorable prognosis.

show abstract

Pathology of cancers of the female genital tract including molecular pathology

Prat

Mutch

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

To better understand pathology reports, gynecologic oncologists must be familiar with the terminology used in gynecologic pathology. This chapter of the FIGO Cancer Report 2018 summarizes the clinical and pathological features of the most common cancers of the female genital tract, as well as their main molecular genetic alterations. In selected cases, an approach for processing surgical specimens is also included.

show abstract

Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments

Cited by 61 publications

References 18 publications

Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors

Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors

BRAF mutational analysis in ovarian tumors: recent perspectives

Pathology of cancers of the female genital tract including molecular pathology

Contact Info

Product

Resources

About